This Week in The Roadhouse Pharmacy

THE ROADHOUSE PHARMACY: There’s a great deal of interest in the Bio-tech sector at the moment, so we have opened our own Pharmacy to keep our readers up to speed.

Ethics approval granted for OncoSil™ Clinical Pivotal Trial

OncoSil Medical Limited (ASX: OSL) has been granted Ethics Approval for the Australian hospital sites for the Pivotal Clinical Trial for the company’s lead product candidate, the OncoSil™ localised radiation therapy treatment for pancreatic cancer.
READ MORE…

Uranex signs MoU with Chinese SOE

Uranex Limited (ASX: UNX) has signed a Memorandum of Understanding (MoU) for an Off-take Agreement with China National Materials Industry Import and Export Corporation (SINOMA).
READ MORE…

FDA grants Starpharma Phase 3 trial

Starpharma Holdings (ASX: SPL) announced the US Food and Drug Administration (FDA) has granted Special Protocol Assessment (SPA) agreement on the design and planned analyses of the phase 3 clinical studies of the VivaGel® bacterial vaginosis (BV) product for the prevention of recurrent BV.
READ MORE…

Probiotec commences clinical trial

Probiotec Limited (ASX: PBP) announced that further to its ongoing research and development program with Griffith University and other research organisations, the company has commenced a clinical trial to investigate the effectiveness of Glycomax Lactoferrin and bovine whey derived Ig rich fraction (Immunoglobulin) for the treatment of atopic dermatitis.
READ MORE…

Cynata Contracts Leading CRO to Conduct Preclinical Studies

Cynata Therapeutics (ASX: CYP) has signed an agreement with WuXi AppTec (NYSE:WX), a leading global biopharmaceutical contract research organisation, to conduct preclinical safety studies with Cynata’s unique Cymerus™ stem cell technology.
READ MORE…